The bill repeals the longstanding exemption that treated hydraulic fracturing separately from underground injection under the Safe Drinking Water Act (SDWA). It amends 42 U.S.C. §300h to explicitly include fluids and propping agents used in hydraulic fracturing for oil, gas, or geothermal production within the SDWA’s definition of underground injection while excluding underground injection of natural gas for storage.
Beyond definitional change, the bill creates a federal disclosure regime: operators must file lists of chemicals (with Chemical Abstracts Service numbers, material safety data sheets where available, and anticipated volumes) before fracturing begins and must file actual chemicals and volumes within 30 days after operations end. States (or EPA where applicable) must post that information online; trade-secret formulas are shielded from public posting but must be disclosed immediately to regulators or treating clinicians in medical emergencies.
This shifts permitting, reporting, and public-information obligations onto operators and state/EPA implementers and raises implementation, confidentiality, and enforcement questions for regulators and industry alike.
At a Glance
What It Does
The bill amends SDWA section 1421 to treat hydraulic fracturing injections as underground injection and requires operators to submit pre-operation chemical lists and a post-operation list within 30 days that include CAS numbers, MSDS, and volumes. It directs the State or EPA to make non‑proprietary chemical information publicly available online and mandates immediate disclosure of proprietary formulas to regulators or treating clinicians in a medical emergency.
Who It Affects
Oil and gas operators and service companies that perform hydraulic fracturing, state primacy agencies and EPA where federal oversight applies, treating physicians and emergency medical personnel, and environmental and public-health organizations that use chemical-disclosure data.
Why It Matters
This creates a federal baseline for chemical transparency in fracking and folds fracking injections into the SDWA regulatory framework, altering permitting and monitoring responsibilities. It also formalizes emergency access to trade-secret information while preserving a public-protection versus commercial-confidentiality trade-off that states and operators will have to manage.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill changes the legal status of hydraulic fracturing injections by amending the Safe Drinking Water Act to say explicitly that underground injection includes fluids and propping agents used in fracking tied to oil, gas, or geothermal extraction. It keeps a carve-out for the underground injection of natural gas for storage, so storage activities remain outside this change.
That definitional switch brings fracking-related injections into the SDWA’s regulatory perimeter and subjects them to the Act’s permitting, monitoring, and oversight architecture to the extent states exercise primacy or EPA steps in.
On disclosure, the bill requires operators to prepare and deliver to the State (or EPA where the Agency has primary enforcement responsibility) a list of chemicals they intend to use at a lease area before fracturing begins. That submission must identify each chemical constituent, include Chemical Abstracts Service (CAS) numbers, provide material safety data sheets when available, and state anticipated volumes.
Operators must then submit a post‑operation report no later than 30 days after operations end, updating the list to show the chemicals actually used and the volumes consumed. The State or EPA must make the disclosed chemical-constituent information available to the public, including by posting it on a suitable website.The bill also addresses proprietary or trade-secret chemicals.
It requires operators to disclose proprietary chemical formulas or the specific identity of trade-secret chemicals immediately to the State, EPA, or a treating physician or nurse when a medical emergency exists — and does so regardless of whether a written statement of need or confidentiality agreement has already been supplied. Operators may require a statement of need and a confidentiality agreement once circumstances permit.
At the same time, the bill prohibits States or EPA from forcing public disclosure of proprietary chemical formulas, preserving a layer of commercial confidentiality while ensuring clinicians and regulators can obtain critical toxicological information in emergencies.Taken together, these provisions create concrete operational obligations for operators (timing, content, and delivery of disclosures) and mandate public transparency for non‑proprietary information while carving out emergency access and confidentiality protections for trade secrets. The statutory text is procedural rather than punitive: it prescribes what must be disclosed and who must post it but leaves the specifics of implementation, verification, and enforcement to regulators and subsequent rulemaking or guidance.
The Five Things You Need to Know
The bill amends 42 U.S.C. §300h(d)(1) to include hydraulic fracturing injections for oil, gas, or geothermal activities in the SDWA definition of 'underground injection' and explicitly excludes underground injection of natural gas for storage.
Operators must submit a pre‑operation list of chemicals intended for use at each lease area before any hydraulic fracturing begins, including chemical constituents, CAS numbers, MSDS when available, and anticipated volumes.
Operators must file a post‑operation chemical report within 30 days after fracturing ends listing chemicals actually used, constituent identities, CAS numbers, MSDS when available, and the volume of each chemical used.
States or EPA must make the chemical-constituent disclosures publicly available (for example, by posting them on a website), but the statute expressly bars public disclosure of proprietary chemical formulas.
In a medical emergency, operators must immediately disclose proprietary formulas or trade‑secret chemical identities to the State, EPA, or the treating physician or nurse, without waiting for a written need statement or confidentiality agreement.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Names the measure the 'Fracturing Responsibility and Awareness of Chemicals Act of 2025.' This is a formal header but signals legislative intent to focus the Act on disclosure, responsibility, and awareness around fracturing chemicals.
Reclassify hydraulic fracturing as 'underground injection'
The amendment strikes the existing subparagraph that created an exemption and inserts language that brings fluids and propping agents used in hydraulic fracturing for oil, gas, or geothermal production squarely within the SDWA’s definition of underground injection. It separately states that underground injection of natural gas for storage is excluded. Practically, this forces regulators and operators to treat fracking injections under the SDWA's statutory framework; states with primacy will implement their regulatory programs, and EPA will retain authority where it has primary enforcement responsibility.
Pre‑ and post‑operation chemical disclosures; content and timing
This provision mandates two distinct filings: a pre‑operation submission listing intended chemicals, their constituent identities, CAS numbers, MSDS if available, and anticipated volumes before fracturing begins at a lease area; and a post‑operation submission within 30 days listing chemicals actually used and the actual volumes. The statute specifies the data elements operators must supply, which creates a predictable compliance checklist but leaves verification, formats, and enforcement details for regulators to define.
Public availability, medical-emergency disclosure, and trade-secret carve‑outs
States or EPA must make the non‑proprietary chemical-constituent disclosures available to the public, including via an internet posting. For medical emergencies, the operator must immediately disclose proprietary formulas or specific trade-secret identities to the State, EPA, or treating physician/nurse without waiting for written need statements or confidentiality agreements; the operator may require those formalities afterward. A separate sentence forbids the State or EPA from compelling public disclosure of proprietary chemical formulas, so while detailed proprietary information can reach clinicians and regulators in emergencies, it is not subject to general public posting.
This bill is one of many.
Codify tracks hundreds of bills on Environment across all five countries.
Explore Environment in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Residents and community groups near fracking operations — they gain access to chemical-constituent lists and volumes for local wells and can use that information to assess potential exposure pathways and push for monitoring.
- Treating physicians, nurses, and emergency medical personnel — they get immediate access to proprietary chemical identities in medical emergencies, improving diagnosis and treatment of exposure incidents.
- State regulators and EPA — the bill gives them clear statutory authority to require data from operators and to collect standardized information that supports oversight, investigations, and public-health responses.
- Environmental and public-health researchers and NGOs — public posting of non‑proprietary chemical data creates a larger, more consistent dataset for risk assessment, epidemiology, and policy analysis.
Who Bears the Cost
- Oil and gas operators and service companies — they must compile and submit pre‑ and post‑operation chemical inventories with CAS numbers, MSDS, and volume data, increasing reporting, recordkeeping, and potential legal-compliance costs.
- States and EPA — agencies must process filings, host and maintain public-facing data systems, and potentially perform oversight and enforcement; that creates administrative and IT costs and may require new rulemaking.
- Companies holding trade-secret formulas (chemical suppliers and service firms) — they face the risk that proprietary information will be disclosed to regulators and clinicians in emergencies and must establish internal controls and legal protocols for disclosures.
- Courts and regulators — the bill may produce new litigation over what qualifies as a proprietary formula, adequacy of disclosures, and timeliness in emergencies, imposing adjudicative or enforcement burdens.
Key Issues
The Core Tension
The central tension is between two legitimate goals: protecting public health through transparency and rapid clinical access to chemical identities, and protecting commercially valuable, proprietary chemical formulations. The bill guarantees emergency access for clinicians and regulators but preserves public secrecy for trade secrets — a compromise that shifts the conflict from whether information is disclosed to how, when, and under what safeguards it is shared and enforced.
The statute sets firm disclosure deadlines and content requirements but leaves significant implementation choices to regulators. It does not specify penalties, inspection regimes, or verification procedures for checking the accuracy of operator disclosures.
That gap creates questions about compliance incentives: if filings are incorrect or incomplete, the statute does not itself create administrative fines or criminal exposure; regulators will need to fill that enforcement vacuum through rulemaking or rely on existing SDWA authorities. The statute also does not define key operational terms — for example, 'lease area,' 'anticipated volume,' or the criteria for what constitutes a 'medical emergency' — leaving space for divergent interpretations between states and EPA and potential legal disputes.
The bill tries to thread a needle on trade secrets: it prevents public posting of proprietary formulas while forcing immediate disclosure to regulators and treating clinicians in emergencies. That raises practical questions about how operators will protect commercially sensitive information once shared with state agencies, how regulators will secure submitted data, and how conflicts with state trade-secret statutes or Freedom of Information Act requests will be resolved.
Operators may respond by increasing use of generic labels or aggregating components to limit disclosure, which could reduce the utility of public data. Finally, the carve-out for underground natural-gas storage could create a narrow pathway for some activities to avoid SDWA coverage, depending on project design and operator behavior; regulators will need clear guidance to prevent circumvention.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.